KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Operating Margin (2016 - 2025)

Nektar Therapeutics has reported Operating Margin over the past 16 years, most recently at 126.86% for Q4 2025.

  • Quarterly results put Operating Margin at 126.86% for Q4 2025, down 17604.0% from a year ago — trailing twelve months through Dec 2025 was 253.66% (down 14678.0% YoY), and the annual figure for FY2025 was 253.66%, down 14678.0%.
  • Operating Margin for Q4 2025 was 126.86% at Nektar Therapeutics, up from 268.63% in the prior quarter.
  • Over the last five years, Operating Margin for NKTR hit a ceiling of 49.18% in Q4 2024 and a floor of 708.07% in Q2 2022.
  • Median Operating Margin over the past 5 years was 257.74% (2025), compared with a mean of 310.79%.
  • Biggest five-year swings in Operating Margin: tumbled -31906bps in 2022 and later surged 46123bps in 2023.
  • Nektar Therapeutics' Operating Margin stood at 451.48% in 2021, then skyrocketed by 47bps to 238.25% in 2022, then surged by 41bps to 140.3% in 2023, then surged by 135bps to 49.18% in 2024, then plummeted by -358bps to 126.86% in 2025.
  • The last three reported values for Operating Margin were 126.86% (Q4 2025), 268.63% (Q3 2025), and 324.21% (Q2 2025) per Business Quant data.